Testing a New Yellow Fever and Dengue Vaccine
Part of Immune system & allergy clinical trials.
This study tests a new vaccine designed to improve protection against yellow fever and dengue fever in healthy adults. Researchers want to see if this vaccine works better than existing ones and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 21 and 59 years old
- Have a healthy weight (BMI 18.5–27.5, based on Asian health guidelines)
- Be in generally good health with stable medical conditions (no hospitalizations in the last 6 months)
- Commit to study visits, keeping a diary, and staying in contact with the research team
- Have accessible veins for blood draws
- For women: be unable to become pregnant (through surgery or menopause for at least 12 months)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how the dengue virus affects healthy adults who have never been exposed to dengue or similar viruses. You would be given a controlled dose of the virus and closely monitored to help researchers understand the infection and develop better treatments or vaccines.
This trial studies how well the yellow fever vaccine “17D” stimulates the immune system (the body’s germ-fighting response) in adults who were vaccinated with 17D years ago. It may help researchers understand whether a prior vaccination still provides protection and how strong the immune response is.
This study looks at how your body's immune system responds to the yellow fever vaccine. It may help researchers understand how well the vaccine protects people.
This trial tests a new dengue vaccine in adults aged 40 to 79 to see if it can protect them from dengue fever. If you are generally healthy and willing to follow the study schedule, you may be able to join.
This study looks at how your immune system “remembers” the yellow fever vaccine over time. It may help researchers understand long-term immune protection and how it varies between people.
This trial tests a new experimental drug, EYU688, for adults with dengue fever. It aims to see if the drug is safe and effective. You may qualify if you have early dengue symptoms, have tested positive for dengue, and are otherwise healthy.
Hear when a new Immune System Responses and Trained Immunity After AS01 Administration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.